Literature DB >> 24626176

Loss of autocrine endothelial-derived VEGF significantly reduces hemangiosarcoma development in conditional p53-deficient mice.

Morvarid Farhang Ghahremani1, Enrico Radaelli2, Katharina Haigh3, Sonia Bartunkova1, Lieven Haenebalcke1, Jean-Christophe Marine4, Steven Goossens5, Jody J Haigh3.   

Abstract

Malignant transformation of the endothelium is rare, and hemangiosarcomas comprise only 1% of all sarcomas. For this reason and due to the lack of appropriate mouse models, the genetic mechanisms of malignant endothelial transformation are poorly understood. Here, we describe a hemangiosarcoma mouse model generated by deleting p53 specifically in the endothelial and hematopoietic lineages. This strategy led to a high incidence of hemangiosarcoma, with an average latency of 25 weeks. To study the in vivo roles of autocrine or endothelial cell autonomous VEGF signaling in the initiation and/or progression of hemangiosarcomas, we genetically deleted autocrine endothelial sources of VEGF in this mouse model. We found that loss of even a single conditional VEGF allele results in substantial rescue from endothelial cell transformation. These findings highlight the important role of threshold levels of autocrine VEGF signaling in endothelial malignancies and suggest a new approach for hemangiosarcoma treatment using targeted autocrine VEGF inhibition.

Entities:  

Keywords:  VEGF; autocrine; endothelial cell; hemangiosarcoma; mouse model; p53

Mesh:

Substances:

Year:  2014        PMID: 24626176      PMCID: PMC4050148          DOI: 10.4161/cc.28474

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  41 in total

1.  Mutations of p53 tumor-suppressor gene in angiosarcoma.

Authors:  N Naka; Y Tomita; H Nakanishi; N Araki; T Hongyo; T Ochi; K Aozasa
Journal:  Int J Cancer       Date:  1997-06-11       Impact factor: 7.396

2.  Establishment of a new murine-phenotypic angiosarcoma cell line (ISOS-1).

Authors:  M Masuzawa; T Fujimura; M Tsubokawa; S Nishiyama; K Katsuoka; E Terada; S Kunita; Y Sakurai; H Kato
Journal:  J Dermatol Sci       Date:  1998-01       Impact factor: 4.563

3.  Effects of genetic background on tumorigenesis in p53-deficient mice.

Authors:  L A Donehower; M Harvey; H Vogel; M J McArthur; C A Montgomery; S H Park; T Thompson; R J Ford; A Bradley
Journal:  Mol Carcinog       Date:  1995-09       Impact factor: 4.784

4.  Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.

Authors:  M Harvey; M J McArthur; C A Montgomery; J S Butel; A Bradley; L A Donehower
Journal:  Nat Genet       Date:  1993-11       Impact factor: 38.330

5.  Genetic background alters the spectrum of tumors that develop in p53-deficient mice.

Authors:  M Harvey; M J McArthur; C A Montgomery; A Bradley; L A Donehower
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

6.  HIF transcription factor expression and induction of hypoxic response genes in a retroperitoneal angiosarcoma.

Authors:  W Kimryn Rathmell; Geza Acs; M Celeste Simon; David J Vaughn
Journal:  Anticancer Res       Date:  2004 Jan-Feb       Impact factor: 2.480

7.  Establishment and characterization of an angiosarcoma-derived cell line, AS-M.

Authors:  Vera Krump-Konvalinkova; Fernando Bittinger; Jürgen Olert; Wolfgang Bräuninger; Joachim Brunner; C James Kirkpatrick
Journal:  Endothelium       Date:  2003

8.  MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas.

Authors:  C Zietz; M Rössle; C Haas; A Sendelhofert; A Hirschmann; M Stürzl; U Löhrs
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

9.  Use of immunohistochemical procedures in diagnosing angiosarcoma. Evaluation of 98 cases.

Authors:  M Ohsawa; N Naka; Y Tomita; D Kawamori; H Kanno; K Aozasa
Journal:  Cancer       Date:  1995-06-15       Impact factor: 6.860

10.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.

Authors:  K M Dameron; O V Volpert; M A Tainsky; N Bouck
Journal:  Science       Date:  1994-09-09       Impact factor: 47.728

View more
  5 in total

1.  ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling.

Authors:  Steven Goossens; Enrico Radaelli; Odile Blanchet; Kaat Durinck; Joni Van der Meulen; Sofie Peirs; Tom Taghon; Cedric S Tremblay; Magdaline Costa; Morvarid Farhang Ghahremani; Jelle De Medts; Sonia Bartunkova; Katharina Haigh; Claire Schwab; Natalie Farla; Tim Pieters; Filip Matthijssens; Nadine Van Roy; J Adam Best; Kim Deswarte; Pieter Bogaert; Catherine Carmichael; Adam Rickard; Santi Suryani; Lauryn S Bracken; Raed Alserihi; Kirsten Canté-Barrett; Lieven Haenebalcke; Emmanuelle Clappier; Pieter Rondou; Karolina Slowicka; Danny Huylebroeck; Ananda W Goldrath; Viktor Janzen; Matthew P McCormack; Richard B Lock; David J Curtis; Christine Harrison; Geert Berx; Frank Speleman; Jules P P Meijerink; Jean Soulier; Pieter Van Vlierberghe; Jody J Haigh
Journal:  Nat Commun       Date:  2015-01-07       Impact factor: 17.694

2.  Mouse genetic background influences whether HrasG12V expression plus Cdkn2a knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma.

Authors:  Laura P Brandt; Joachim Albers; Tomas Hejhal; Svende Pfundstein; Ana Filipa Gonçalves; Antonella Catalano; Peter J Wild; Ian J Frew
Journal:  Oncotarget       Date:  2018-04-13

3.  Development of mouse models of angiosarcoma driven by p53.

Authors:  Donald M Salter; Meredyth Griffin; Morwenna Muir; Katy Teo; Jayne Culley; James R Smith; Laura Gomez-Cuadrado; Kylie Matchett; Andrew H Sims; Larry Hayward; Neil C Henderson; Valerie G Brunton
Journal:  Dis Model Mech       Date:  2019-07-09       Impact factor: 5.758

4.  p53 siRNA - a therapeutic tool with significant implication in the modulation of apoptosis and angiogenic pathways.

Authors:  Ovidiu Braicu; Valentina Pileczki; Cornelia Braicu; Patriciu Achimas-Cadariu; Alexandru Irimie; Ioana Berindan-Neagoe
Journal:  Clujul Med       Date:  2015-07-01

5.  In vitro effects of PI3K/mTOR inhibition in canine hemangiosarcoma.

Authors:  Alex A Pyuen; Travis Meuten; Barbara J Rose; Douglas H Thamm
Journal:  PLoS One       Date:  2018-07-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.